Taken together, IL-6 serum levels are another imperfect biomarker for IBD activity but may be useful for identifying patients with a particularly strong IL-6 disease signature in order to increase the likelihood of treatment success with drugs targeting IL-6 or its signalling pathways. Here, IL6 is linked to inflammatory bowel disease.